Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In Marex To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $10,000 in Marex between May 16, 2024 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Marex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Marex between May 16, 2024 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status by December 8, 2025 [1][3]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements [3]. - A report from NINGI Research accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions, including a fabricated receivable of $17 million and nearly $1 billion in concealed derivatives exposure [4]. - Following the release of the report, Marex's stock experienced a decline of 6.2%, closing at $35.31 on heavy trading volume [5]. Group 2: Legal Proceedings and Investor Actions - The lead plaintiff in the class action lawsuit will be the investor with the largest financial interest who is adequate and typical of class members, and any member of the class may move to serve as lead plaintiff [6]. - Faruqi & Faruqi encourages individuals with information regarding Marex's conduct, including whistleblowers and former employees, to contact the firm [6].

Core Viewpoint - Marex Group plc is facing a class action lawsuit due to allegations of engaging in a multi-year accounting scheme that misled investors about its financial health and risk exposure [3]. Group 1: Legal Action - The Portnoy Law Firm is advising Marex Group plc investors to join a class action lawsuit for those who purchased securities between May 16, 2024, and August 5, 2025 [1]. - Investors have until December 8, 2025, to file a lead plaintiff motion [1]. - The law firm offers complimentary case evaluations and options for investors to recover losses [2]. Group 2: Financial Allegations - A report by NINGI Research claims that Marex has been involved in a deceptive accounting scheme, utilizing off-balance-sheet entities and fictitious transactions to hide losses and inflate profits [3]. - Following the release of this report, Marex's stock price dropped by $2.33, or 6.19%, closing at $35.31 per share on August 5, 2025 [3]. Group 3: Law Firm Background - The Portnoy Law Firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by December 8, 2025 [4][6]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [6]. - Specific allegations include a multi-year accounting scheme involving off-balance-sheet entities, fictitious transactions, and misleading disclosures to hide losses and inflate profits, with examples such as a $17 million fabricated receivable and nearly $1 billion in concealed derivatives exposure [7]. - Following the release of a report by NINGI Research, Marex's stock experienced a significant drop of 6.2%, closing at $35.31 on heavy trading volume [8]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased Marex securities between May 16, 2024, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][10]. - The role of lead plaintiff in the class action is designated to the investor with the largest financial interest who is typical of class members, with the option for any member to move the court to serve as lead plaintiff [9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status by December 8, 2025 [1][3]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements [3]. - A report from NINGI Research accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions, including a fabricated receivable of $17 million and nearly $1 billion in concealed derivatives exposure [4]. - Following the release of the report, Marex's stock experienced a significant drop of 6.2%, closing at $35.31 [5]. Group 2: Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is adequate and typical of class members, with options for other members to participate or remain absent [6]. - Faruqi & Faruqi encourages anyone with information regarding Marex's conduct to come forward, including whistleblowers and former employees [6].

Core Viewpoint - A class action lawsuit has been filed against Marex Group plc for alleged securities fraud, with claims of significant accounting irregularities and misleading disclosures impacting investors [1][5]. Group 1: Allegations and Findings - A report by NINGI Research on August 5, 2025, accused Marex of engaging in a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions to conceal losses and inflate profits [3]. - The report highlighted discrepancies, including a $17 million receivable created without basis, a subsidiary's profit inflated by 150%, and an asset sold for $2.5 million that was previously valued at $14.9 million [3]. - It was alleged that Marex concealed nearly $1 billion in off-balance-sheet derivatives exposure through a Luxembourg fund, misclassifying structured note issuance as income to inflate cash flow [3]. Group 2: Market Reaction - Following the publication of the report, Marex's stock price dropped by $2.33, or 6.2%, closing at $35.31 per share on August 5, 2025, with unusually high trading volume [4]. Group 3: Lawsuit Details - The class action complaint claims that Marex's management made materially false statements and failed to disclose adverse facts about the company's financial health, including inconsistencies in financial statements and reliance on misleading positive statements [5]. - Specific allegations include the sale of over-the-counter financial instruments to itself and the unreliability of Marex's financial statements due to discrepancies in intercompany transactions [5].

Core Viewpoint - Marex Group plc is under investigation for potential violations of federal securities laws, following allegations of a multi-year accounting scheme that concealed significant losses and inflated profits [2]. Group 1: Investigation Details - NINGI Research published a report on August 5, 2025, alleging that Marex engaged in a complex accounting scheme involving off-balance-sheet entities and misleading disclosures [2]. - The report claims that Marex concealed nearly $1 billion in off-balance-sheet derivatives exposure through a Luxembourg fund, which it controls and trades with [2]. - The company is accused of generating non-cash trading profits and inflating operating cash flow by misclassifying structured note issuance as income [2]. Group 2: Market Reaction - Following the news of the investigation, Marex's stock price fell by $2.33, or 6.2%, closing at $35.31 per share on August 5, 2025 [3].

Core Viewpoint - Holzer & Holzer, LLC is investigating Marex Group plc for potential violations of federal securities laws following allegations of a multi-year accounting scheme that involved off-balance-sheet entities and misleading disclosures, leading to a significant drop in the company's stock price [1] Company Investigation - NINGI Research released a report claiming that Marex engaged in a scheme to conceal losses and inflate profits through opaque accounting practices [1] - The investigation by Holzer & Holzer aims to determine if Marex complied with federal securities laws in light of these allegations [1] Stock Performance - Following the release of the allegations, Marex's stock price experienced a decline, indicating a negative market reaction to the news [1]